Analyses from these two trials, including 476 kidney disease progression outcomes in participants with a non-diabetic cause of CKD reported that the relative effects of SGLT2 inhibition appeared similar across the different primary kidney diagnoses (P for heterogeneity between groupings of primary kidney disease=0·67).5 The meta-analysis did not present any details of effects of SGLT2 inhibition on eGFR slopes, albuminuria, blood pressure, hospitalisation or safety outcomes, nor specific baseline characteristics. The gene discussed is SLC5A2; the disease is chronic kidney disease.